RxDoctor Payments Data

Sabah Kadhium, MD

Family Medicine · San Dimas, CANPI 1306836770

Payments from drug & device makers

$6,466in general payments, 2019–2025

Across 342 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$844
  • Teva Pharmaceuticals USA, Inc.$719
  • Pfizer$679
  • Novo Nordisk$484
  • Lilly USA, LLC$446
  • Sunovion Pharmaceuticals Inc.$333
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$6,466100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,466 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$997,360
Medicare patients
729
Services billed
12,484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban724$259,133
OzempicSemaglutide137$150,960
XareltoRivaroxaban279$137,459
AustedoDeutetrabenazine69$133,169
JardianceEmpagliflozin138$125,343
IngrezzaValbenazine Tosylate25$84,896
LinzessLinaclotide71$50,368
SantylCollagenase Clostridium Hist.76$46,726
JanuviaSitagliptin Phosphate65$43,043
TivicayDolutegravir Sodium11$38,188
TrulicityDulaglutide38$37,014
JanumetSitagliptin Phos/Metformin Hcl34$36,879
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog219$34,446
ProliaDenosumab18$31,703
MyrbetriqMirabegron62$28,831

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$679$259,133724 claims
Johnson & JohnsonXarelto, Procrit$844$158,791295 claims
Boehringer IngelheimJardiance, Tradjenta$204$151,495187 claims
Novo NordiskOzempic$484$150,960137 claims
Teva Pharmaceuticals USA, Inc.Austedo$719$133,16969 claims
Neurocrine Biosciences, Inc.Ingrezza$98$84,89625 claims
MerckJanuvia, Janumet$22$79,92299 claims
Lilly USA, LLCTrulicity, Mounjaro$446$64,84267 claims
AmgenProlia, Epogen$208$53,60765 claims
AbbVieLinzess$298$50,36871 claims
Astellas Pharma US IncMyrbetriq$86$28,83162 claims
Avanir Pharmaceuticals, Inc.Nuedexta$26$24,31531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in San Dimas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →